113 related articles for article (PubMed ID: 15196591)
1. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels.
Moghimi SM; Hunter AC; Dadswell CM; Savay S; Alving CR; Szebeni J
Biochim Biophys Acta; 2004 Jun; 1689(2):103-13. PubMed ID: 15196591
[TBL] [Abstract][Full Text] [Related]
2. Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100.
Hamad I; Hunter AC; Moghimi SM
J Control Release; 2013 Sep; 170(2):167-74. PubMed ID: 23747733
[TBL] [Abstract][Full Text] [Related]
3. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels.
Moein Moghimi S; Hamad I; Bünger R; Andresen TL; Jørgensen K; Hunter AC; Baranji L; Rosivall L; Szebeni J
J Liposome Res; 2006; 16(3):167-74. PubMed ID: 16952871
[TBL] [Abstract][Full Text] [Related]
4. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
5. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins.
Szebeni J
Curr Drug Deliv; 2005 Oct; 2(4):443-9. PubMed ID: 16305447
[TBL] [Abstract][Full Text] [Related]
6. Role of atheroma liposomes and malondialdehyde-modified low-density lipoproteins in complement activation.
Sorace JM; Rollins S; Aniagolu JU; Mergner WJ; Cole K; Swartz GM; Green SJ
Pathobiology; 1996; 64(2):73-8. PubMed ID: 8888272
[TBL] [Abstract][Full Text] [Related]
7. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production.
Moghimi SM; Hamad I; Andresen TL; Jørgensen K; Szebeni J
FASEB J; 2006 Dec; 20(14):2591-3. PubMed ID: 17065229
[TBL] [Abstract][Full Text] [Related]
8. Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model.
Andersson J; Bexborn F; Klinth J; Nilsson B; Ekdahl KN
J Biomed Mater Res A; 2006 Jan; 76(1):25-34. PubMed ID: 16250010
[TBL] [Abstract][Full Text] [Related]
9. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.
Chanan-Khan A; Szebeni J; Savay S; Liebes L; Rafique NM; Alving CR; Muggia FM
Ann Oncol; 2003 Sep; 14(9):1430-7. PubMed ID: 12954584
[TBL] [Abstract][Full Text] [Related]
10. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity reactions to intravenous lipid emulsion in swine: relevance for lipid resuscitation studies.
Bedocs P; Capacchione J; Potts L; Chugani R; Weiszhar Z; Szebeni J; Buckenmaier CC
Anesth Analg; 2014 Nov; 119(5):1094-101. PubMed ID: 25126705
[TBL] [Abstract][Full Text] [Related]
12. Poloxamer 188 enhances apoptosis in a human leukemia cell line.
Aoki N; Tamura M; Ohyashiki JH; Sugaya M; Hisatomi H
Mol Med Rep; 2010; 3(4):669-72. PubMed ID: 21472296
[TBL] [Abstract][Full Text] [Related]
13. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.
Hamad I; Hunter AC; Szebeni J; Moghimi SM
Mol Immunol; 2008 Dec; 46(2):225-32. PubMed ID: 18849076
[TBL] [Abstract][Full Text] [Related]
15. Anaphylaxis Due to Poloxamer 238.
Carbonell A; Escudero AI; Miralles JC; González A; Navarro C; Cardona P; Jimeno L; Pineda F
J Investig Allergol Clin Immunol; 2018 Dec; 28(6):419-420. PubMed ID: 30530388
[No Abstract] [Full Text] [Related]
16. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
Korolenko TA; Tuzikov FV; Cherkanova MS; Johnston TP; Tuzikova NA; Loginova VM; Filjushina EE; Kaledin VI
Can J Physiol Pharmacol; 2012 Feb; 90(2):141-53. PubMed ID: 22320860
[TBL] [Abstract][Full Text] [Related]
17. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
18. Complement activation in hypercholesterolemia.
Pasqui AL; Bova G; Puccetti L; Bruni F; Pompella G; Auteri A
Nutr Metab Cardiovasc Dis; 2000 Jun; 10(3):137-42. PubMed ID: 11006922
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
Szebeni J
Drug Discov Today; 2018 Mar; 23(3):487-492. PubMed ID: 29326077
[TBL] [Abstract][Full Text] [Related]
20. The interaction of liposomes with the complement system.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 1998; 15(1):57-88. PubMed ID: 9523086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
